Hit discovery and hit-to-lead approaches
- 1 August 2006
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 11 (15-16) , 741-748
- https://doi.org/10.1016/j.drudis.2006.06.016
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel SynthesisJournal of Medicinal Chemistry, 2005
- Structure-Based Virtual Screening for Low Molecular Weight Chemical Starting Points for Dipeptidyl Peptidase IV InhibitorsJournal of Medicinal Chemistry, 2005
- Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2Bioorganic & Medicinal Chemistry Letters, 2004
- SpeedScreen: The “Missing Link” between Genomics and Lead DiscoverySLAS Discovery, 2004
- Molecular Informatics as an Enabling in silico Technology Platform for Drug DiscoveryChimia, 2004
- Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 HelicaseJournal of Medicinal Chemistry, 2003
- A ‘Rule of Three’ for fragment-based lead discovery?Drug Discovery Today, 2003
- Identification of “Latent Hits” in Compound Screening CollectionsJournal of Medicinal Chemistry, 2003
- Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical PropertiesJournal of Medicinal Chemistry, 2001
- NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 ProteinJournal of Medicinal Chemistry, 1997